Gjumrakch Aliev

List of Publications by Year
in descending order

250	14,555	31902	22102
papers	citations	53 h-index	113 g-index

271	271	271	20253
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	4.3	2,064
2	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	0.9	1,670
3	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	1.7	1,179
4	Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Journal of Neurochemistry, 2001, 76, 435-441.	2.1	419
5	Role of mitochondrial dysfunction in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 357-360.	1.3	324
6	Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of Ï„ Filament Formation. American Journal of Pathology, 2003, 162, 1623-1627.	1.9	294
7	Is oxidative damage the fundamental pathogenic mechanism of Alzheimerâ€™s and other neurodegenerative diseases?. Free Radical Biology and Medicine, 2002, 33, 1475-1479.	1.3	266
8	Sol-gel synthesis of thorn-like ZnO nanoparticles endorsing mechanical stirring effect and their antimicrobial activities: Potential role as nano-antibiotics. Scientific Reports, 2016, 6, 27689.	1.6	256
9	Nucleic acid oxidation in Alzheimer disease. Free Radical Biology and Medicine, 2008, 44, 1493-1505.	1.3	188
10	Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 9, 147-153.	1.2	167
11	Vascular oxidative stress in Alzheimer disease. Journal of the Neurological Sciences, 2007, 257, 240-246.	0.3	164
12	Increased Autophagic Degradation of Mitochondria in Alzheimer Disease. Autophagy, 2007, 3, 614-615.	4.3	147
13	The Role of Oxidative Stress in the Pathophysiology of Cerebrovascular Lesions in Alzheimer's Disease. Brain Pathology, 2002, 12, 21-35.	2.1	146
14	Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 525-532.	0.9	138
15	Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System. CNS and Neurological Disorders - Drug Targets, 2016, 15, 329-336.	0.8	138
16	Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotoxicity Research, 2003, 5, 491-504.	1.3	134
17	Neuroinflammation in Alzheimer's Disease. Advances in Protein Chemistry and Structural Biology, 2017, 108, 33-57.	1.0	129
18	Antioxidant Therapy in Alzheimers Disease: Theory and Practice. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1395-1406.	1.1	129

#	Article	IF	Citations
19	Biogenic synthesis of Zinc oxide nanostructures from Nigella sativa seed: Prospective role as food packaging material inhibiting broad-spectrum quorum sensing and biofilm. Scientific Reports, 2016, 6, 36761.	1.6	128
20	Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers. Seminars in Cancer Biology, 2022, 83, 556-569.	4.3	128
21	Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease. Current Medicinal Chemistry, 2014, 21, 2208-2217.	1.2	127
22	Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology. Current Alzheimer Research, 2005, 2, 403-408.	0.7	117
23	Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radical Biology and Medicine, 2005, 38, 746-754.	1.3	115
24	Inhibition of Vascular Nitric Oxide after Rat Chronic Brain Hypoperfusion: Spatial Memory and Immunocytochemical Changes. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 663-672.	2.4	114
25	Mitochondrial failures in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 345-352.	0.9	111
26	The Role of Polyphenolic Antioxidants in Health, Disease, and Aging. Rejuvenation Research, 2010, 13, 631-643.	0.9	111
27	Neuronal RNA Oxidation in Alzheimer's Disease and Down's Syndrome. Annals of the New York Academy of Sciences, 1999, 893, 362-364.	1.8	107
28	Oxidative damage in Alzheimer's disease: the metabolic dimension. International Journal of Developmental Neuroscience, 2000, 18, 417-421.	0.7	106
29	Neuronal mitochondrial amelioration by feeding acetylâ€Lâ€carnitine and lipoic acid to aged rats. Journal of Cellular and Molecular Medicine, 2009, 13, 320-333.	1.6	105
30	Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. Journal of Alzheimer's Disease, 2004, 6, 165-169.	1.2	100
31	Sleep Disorders Associated With Alzheimer's Disease: A Perspective. Frontiers in Neuroscience, 2018, 12, 330.	1.4	99
32	The Possibility of an Infectious Etiology of Alzheimer Disease. Molecular Neurobiology, 2019, 56, 4479-4491.	1.9	99
33	Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurological Research, 2003, 25, 665-674.	0.6	93
34	Antioxidants in Health, Disease and Aging. CNS and Neurological Disorders - Drug Targets, 2011, 10, 192-207.	0.8	92
35	Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. International Journal of Biochemistry and Cell Biology, 2009, 41, 1989-2004.	1.2	91
36	Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. , 2020, 207, 107464.		91

#	Article	IF	Citations
37	Atherosclerotic Lesions and Mitochondria DNA Deletions in Brain Microvessels as a Central Target for the Development of Human AD and ADâ€Like Pathology in Aged Transgenic Mice. Annals of the New York Academy of Sciences, 2002, 977, 45-64.	1.8	88
38	Nitric Oxide as an Initiator of Brain Lesions During the Development of Alzheimer Disease. Neurotoxicity Research, 2009, 16, 293-305.	1.3	88
39	The effect of acetyl-L-carnitine and R-Î±-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. Journal of the Neurological Sciences, 2009, 283, 199-206.	0.3	85
40	Positive modulators of the Î±7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. Progress in Neurobiology, 2016, 144, 142-157.	2.8	85
41	Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?. CNS and Neurological Disorders - Drug Targets, 2011, 10, 184-191.	0.8	84
42	Microbial Enzymatic Degradation of Biodegradable Plastics. Current Pharmaceutical Biotechnology, 2017, 18, 429-440.	0.9	83
43	Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion, 2004, 4, 649-663.	1.6	77
44	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotoxicity Research, 2006, 10, 43-56.	1.3	76
45	Conjugates of Î³-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. Scientific Reports, 2015, 5, 13164.	1.6	76
46	The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy, 2018, Volume 12, 1147-1156.	2.0	75
47	Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents. European Journal of Medicinal Chemistry, 2016, 112, 289-297.	2.6	71
48	Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease. Current Topics in Medicinal Chemistry, 2017, 17, 1331-1335.	1.0	70
49	Extracellular vesicles in cancer nanomedicine. Seminars in Cancer Biology, 2021, 69, 212-225.	4.3	69
50	Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology, 2022, 83, 452-471.	4.3	64
51	Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. Current Pharmaceutical Design, 2016, 22, 812-818.	0.9	60
52	Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacological Research, 2018, 129, 216-226.	3.1	56
53	Integrated treatment approach improves cognitive function in demented and clinically depressed patients. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 21-26.	0.9	55
54	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. Journal of the Neurological Sciences, 2005, 229-230, 285-292.	0.3	55

#	Article	IF	Citations
55	Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment. Scientific Reports, 2017, 7, 45627.	1.6	54
56	Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 149-162.	0.8	54
57	Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease. Vascular Health and Risk Management, 2008, Volume 4, 721-730.	1.0	53
58	Circular RNAs as biomarkers and therapeutic targets in cancer. Seminars in Cancer Biology, 2022, 83, 242-252.	4.3	53
59	Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis. Current Topics in Medicinal Chemistry, 2017, 17, 1438-1447.	1.0	53
60	Alterations of Astrocytes in the Context of Schizophrenic Dementia. Frontiers in Pharmacology, 2019, 10, 1612.	1.6	52
61	A metabolic basis for Alzheimer disease. Neurochemical Research, 2003, 28, 1549-1552.	1.6	51
62	Implications of nanotechnology for the treatment of cancer: Recent advances. Seminars in Cancer Biology, 2021, 69, 190-199.	4.3	50
63	Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases. Recent Patents on Cardiovascular Drug Discovery, 2011, 6, 222-241.	1.5	50
64	Link between Cancer and Alzheimer Disease via Oxidative Stress Induced by Nitric Oxide-Dependent Mitochondrial DNA Overproliferation and Deletion. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-19.	1.9	49
65	Molecular Mechanisms of Drug Photodegradation and Photosensitization. Current Pharmaceutical Design, 2016, 22, 768-782.	0.9	47
66	Astrocytes and endoplasmic reticulum stress: A bridge between obesity and neurodegenerative diseases. Progress in Neurobiology, 2017, 158, 45-68.	2.8	43
67	Oxidative damage and Alzheimer's disease: Are antioxidant therapies useful?. Drug News and Perspectives, 2005, 18, 5.	1.9	43
68	The Links between Parkinsonâ€™s Disease and Cancer. Biomedicines, 2020, 8, 416.	1.4	42
69	Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment. Pharmacological Research, 2021, 164, 105277.	3.1	42
70	Alzheimerâ€™s Disease â€“ Future Therapy Based on Dendrimers. Current Neuropharmacology, 2019, 17, 288-294.	1.4	42
71	Novel Therapeutic Strategies for Dementia. CNS and Neurological Disorders - Drug Targets, 2016, 15, 141-241.	0.8	42
72	Pathogenesis of Alzheimer Disease: Role of Oxidative Stress, Amyloid-β Peptides, Systemic Ammonia and Erythrocyte Energy Metabolism. CNS and Neurological Disorders - Drug Targets, 2014, 13, 112-119.	0.8	41

#	Article	IF	Citations
73	Nanotechnology for Alzheimer Disease. Current Alzheimer Research, 2017, 14, 1182-1189.	0.7	41
74	Therapeutic Potentials of Triterpenes in Diabetes and its Associated Complications. Current Topics in Medicinal Chemistry, 2016, 16, 2532-2542.	1.0	41
75	Neurophysiology and Psychopathology Underlying PTSD and Recent Insights into the PTSD Therapiesâ€"A Comprehensive Review. Journal of Clinical Medicine, 2020, 9, 2951.	1.0	40
76	Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders. Current Drug Metabolism, 2017, 18, 112-119.	0.7	40
77	Glutenase and collagenase activities of wheat cysteine protease Triticain-Î±: Feasibility for enzymatic therapy assays. International Journal of Biochemistry and Cell Biology, 2015, 62, 115-124.	1.2	39
78	Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radical Biology and Medicine, 2012, 52, 699-704.	1.3	38
79	Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization. Current Alzheimer Research, 2014, 11, 422-429.	0.7	38
80	Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications. Current Medicinal Chemistry, 2019, 25, 5347-5371.	1.2	37
81	Medicinal Plants as Protective Strategies Against Parkinson's Disease. Current Pharmaceutical Design, 2017, 23, 4180-4188.	0.9	37
82	Age-Related Defects in Erythrocyte 2,3-Diphosphoglycerate Metabolism in Dementia. , 2013, 04, 244-255.		36
83	Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease. Pharmaceuticals, 2010, 3, 158-187.	1.7	35
84	Can miRNAs Be Considered as Diagnostic and Therapeutic Molecules in Ischemic Stroke Pathogenesis?â€"Current Status. International Journal of Molecular Sciences, 2020, 21, 6728.	1.8	35
85	Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Current Pharmaceutical Design, 2016, 22, 819-848.	0.9	35
86	Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia: Probing for Markers. CNS and Neurological Disorders - Drug Targets, 2012, 11, 926-932.	0.8	35
87	Blockade of Neuroglobin Reduces Protection of Conditioned Medium from Human Mesenchymal Stem Cells in Human Astrocyte Model (T98G) Under a Scratch Assay. Molecular Neurobiology, 2018, 55, 2285-2300.	1.9	34
88	Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis. Frontiers in Pharmacology, 2020, 11, 403.	1.6	34
89	Depression of Endothelial Nitric Oxide Synthase but Increased Expression of Endothelin-1 Immunoreactivity in Rat Thoracic Aortic Endothelium Associated With Long-term, but Not Short-term, Sympathectomy. Circulation Research, 1996, 79, 317-323.	2.0	34
90	Atherosclerotic Lesions Are Associated with Increased Immunoreactivity for Inducible Nitric Oxide Synthase and Endothelin-1 in Thoracic Aortic Intimal Cells of Hyperlipidemic Watanabe Rabbits. Experimental and Molecular Pathology, 2001, 71, 40-54.	0.9	33

#	Article	IF	Citations
91	The GRK2 Overexpression Is a Primary Hallmark of Mitochondrial Lesions during Early Alzheimer Disease. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-14.	0.8	32
92	Beyond Mitochondria, What Would be the Energy Source of the Cell?. Central Nervous System Agents in Medicinal Chemistry, 2015, 15, 32-41.	0.5	32
93	Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic Diseases. Current Pharmaceutical Design, 2018, 23, 6321-6346.	0.9	32
94	Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor. Medicinal Chemistry, 2016, 12, 204-210.	0.7	32
95	Editorial [Hot Topic: Oxidative Stress Induced-Metabolic Imbalance, Mitochondrial Failure, And Cellular Hypoperfusion As Primary Pathogenetic Factors For The Development Of Alzheimer Disease Which Can Be Used As An Alternate And Successful Drug Treatment Strategy: Past, Present And Future (Guest Editor: Giumrakch Aliev)]. CNS and Neurological Disorders - Drug Targets, 2011, 10, 147-148.	0.8	31
96	The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives. Seminars in Cancer Biology, 2022, 82, 35-59.	4.3	31
97	Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders. CNS and Neurological Disorders - Drug Targets, 2016, 15, 310-320.	0.8	31
98	Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. Journal of Nuclear Medicine, 2002, 43, 1044-51.	2.8	30
99	Is Non-Genetic Alzheimer's disease a Vascular Disorder with Neurodegenerative Consequences?. Journal of Alzheimer's Disease, 2002, 4, 513-516.	1.2	29
100	Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits. Frontiers in Bioscience - Landmark, 2015, 20, 892-901.	3.0	29
101	Increased Pain Sensitivity in Obese Patients After Lung Cancer Surgery. Frontiers in Pharmacology, 2019, 10, 626.	1.6	29
102	Hypoperfusion, Mitochondria Failure, Oxidative Stress, and Alzheimer Disease. Journal of Biomedicine and Biotechnology, 2003, 2003, 162-163.	3.0	28
103	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. Neurological Research, 2004, 26, 547-553.	0.6	28
104	Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?. Current Alzheimer Research, 2017, 14, 1155-1163.	0.7	28
105	Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease. CNS and Neurological Disorders - Drug Targets, 2016, 15, 292-300.	0.8	28
106	Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review. Advances in Therapy, 2020, 37, 2580-2603.	1.3	27
107	Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. Seminars in Cancer Biology, 2019, 56, 128-134.	4.3	26
108	The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy. Current Pharmaceutical Design, 2015, 21, 3582-3588.	0.9	26

#	Article	IF	Citations
109	Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion. Current Alzheimer Research, 2011, 8, 868-875.	0.7	25
110	Conjugates of methylene blue with Î³-carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases. Scientific Reports, 2019, 9, 4873.	1.6	25
111	The Role of Exosomes in Stemness and Neurodegenerative Diseasesâ€"Chemoresistant-Cancer Therapeutics and Phytochemicals. International Journal of Molecular Sciences, 2020, 21, 6818.	1.8	25
112	Ca²⁺-Myristoyl Switch in Neuronal Calcium Sensor-1: A Role of C-Terminal Segment. CNS and Neurological Disorders - Drug Targets, 2015, 14, 437-451.	0.8	25
113	Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?. Brain Pathology, 2003, 13, 630-638.	2.1	24
114	Conditioned Medium of Human Adipose Mesenchymal Stem Cells Increases Wound Closure and Protects Human Astrocytes Following Scratch Assay In Vitro. Molecular Neurobiology, 2018, 55, 5377-5392.	1.9	23
115	Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 728.	1.4	23
116	Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder. Current Pharmaceutical Design, 2015, 21, 3589-3595.	0.9	23
117	The Links between Cardiovascular Diseases and Alzheimer's Disease. Current Neuropharmacology, 2020, 19, 152-169.	1.4	23
118	Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. The Anatomical Record, 2000, 260, 16-25.	2.3	22
119	RGD-based Therapy: Principles of Selectivity. Current Pharmaceutical Design, 2016, 22, 925-932.	0.9	21
120	Exosomes: Insights from Retinoblastoma and Other Eye Cancers. International Journal of Molecular Sciences, 2020, 21, 7055.	1.8	21
121	The role of nitric oxide in the pathogenesis of brain lesions during the development of Alzheimer's disease. In Vivo, 2004, 18, 325-33.	0.6	21
122	Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease. CNS and Neurological Disorders - Drug Targets, 2016, 15, 113-123.	0.8	20
123	Probiotics: Supplements, Food, Pharmaceutical Industry. , 2018, , 15-25.		20
124	The protective effect of piperine against isoproterenol-induced inflammation in experimental models of myocardial toxicity. European Journal of Pharmacology, 2020, 885, 173524.	1.7	20
125	Serum amyloid P is not present in amyloid Î² deposits of a transgenic animal modela. NeuroReport, 1999, 10, 3229-3232.	0.6	19
126	In vivo and in vitro assessment of brain bioenergetics in aging rats. Journal of Cellular and Molecular Medicine, 2010, 14, 2667-2674.	1.6	19

#	Article	IF	Citations
127	Portacaval shunting causes differential mitochondrial superoxide production in brain regions. Free Radical Biology and Medicine, 2017, 113, 109-118.	1.3	19
128	Extracts of Physalis peruviana Protect Astrocytic Cells Under Oxidative Stress With Rotenone. Frontiers in Chemistry, 2018, 6, 276.	1.8	19
129	MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas. International Journal of Molecular Sciences, 2020, 21, 7287.	1.8	19
130	Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound. CNS and Neurological Disorders - Drug Targets, 2016, 15, 102-107.	0.8	18
131	Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2017, 16, 677-685.	0.8	18
132	Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. Journal of Cellular and Molecular Medicine, 2009, 13, 853-865.	1.6	17
133	Cotinine: A Therapy for Memory Extinction in Post-traumatic Stress Disorder. Molecular Neurobiology, 2018, 55, 6700-6711.	1.9	17
134	Sleep Disturbances and Cognitive Impairment in the Course of Type 2 Diabetes-A Possible Link. Current Neuropharmacology, 2020, 19, 78-91.	1.4	17
135	Implication of the Nutritional and Nonnutritional Factors in the Context of Preservation of Cognitive Performance in Patients With Dementia/Depression and Alzheimer Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 660-670.	0.9	16
136	The mystery of claustral neural circuits and recent updates on its role in neurodegenerative pathology. Behavioral and Brain Functions, 2021, 17, 8.	1.4	16
137	The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer. Current Genomics, 2020, 21, 444-453.	0.7	16
138	The Dawn of Mitophagy: What Do We Know by Now?. Current Neuropharmacology, 2020, 19, 170-192.	1.4	16
139	Drug Therapy in Alzheimer's Disease. New England Journal of Medicine, 2004, 351, 1911-1913.	13.9	15
140	Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-Î²Vaccine. BioMed Research International, 2013, 2013, 1-12.	0.9	15
141	Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches. Journal of Molecular Neuroscience, 2016, 58, 483-492.	1.1	15
142	Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications. Current Pharmaceutical Design, 2017, 23, 4475-4483.	0.9	15
143	The Key Role of Oxidative Stress in Alzheimer's Disease. , 2007, , 267-281.		14
144	Advances in Medicinal Plants with Effects on Anxiety Behavior Associated to Mental and Health Conditions. Current Medicinal Chemistry, 2017, 24, 411-423.	1.2	14

#	Article	IF	Citations
145	Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs. Current Medicinal Chemistry, 2019, 25, 5293-5314.	1.2	14
146	Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome. Current Pharmaceutical Design, 2016, 22, 895-903.	0.9	14
147	Urotensin II: Molecular Mechanisms of Biological Activity. Current Protein and Peptide Science, 2018, 19, 924-934.	0.7	14
148	Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players. Current Topics in Medicinal Chemistry, 2017, 17, 1429-1437.	1.0	14
149	How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions. Current Topics in Medicinal Chemistry, 2019, 19, 394-412.	1.0	14
150	Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies. CNS and Neurological Disorders - Drug Targets, 2014, 13, 467-477.	0.8	14
151	Application of Acyzol in the Context of Zinc Deficiency and Perspectives. International Journal of Molecular Sciences, 2019, 20, 2104.	1.8	13
152	Ocular Paraneoplastic Syndromes. Biomedicines, 2020, 8, 490.	1.4	13
153	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). BioMed Research International, 2021, 2021, 1-20.	0.9	13
154	Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index. Current Pharmaceutical Design, 2016, 22, 792-803.	0.9	13
155	Securinine Derivatives as Potential Anti-amyloid Therapeutic Approach. CNS and Neurological Disorders - Drug Targets, 2017, 16, 351-355.	0.8	13
156	Impact of Amyloid Î²25-35 on Membrane Stability, Energy Metabolism, and Antioxidant Enzymes in Erythrocytes. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 685-695.	0.9	12
157	Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Scientific Reports, 2017, 7, 16072.	1.6	12
158	New Therapeutic Property of Dimebon as a Neuroprotective Agent. Current Medicinal Chemistry, 2019, 25, 5315-5326.	1.2	12
159	The Effect of Short-Term Physical Activity on the Oxidative Stress in Rats with Different Stress Resistance Profiles in Cerebral Hypoperfusion. Molecular Neurobiology, 2020, 57, 3014-3026.	1.9	12
160	Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders. Current Medicinal Chemistry, 2019, 25, 5327-5346.	1.2	12
161	The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents. Current Medicinal Chemistry, 2021, 28, 8139-8162.	1.2	12
162	A proteomics based approach for the identification of gastric cancer related markers. Current Pharmaceutical Design, 2016, 22, 804-811.	0.9	12

#	Article	IF	Citations
163	Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis. CNS and Neurological Disorders - Drug Targets, 2015, 14, 1235-1242.	0.8	12
164	Microglial dependent protective effects of neuroactive steroids. CNS and Neurological Disorders - Drug Targets, 2016, 15, 242-249.	0.8	12
165	Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities. Scientific Reports, 2017, 7, 8309.	1.6	11
166	Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique. Current Pharmaceutical Design, 2016, 22, 870-878.	0.9	10
167	Stem cell niches as clinical targets: the future of anti-ischemic therapy?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 590-591.	3.3	9
168	Dopaminergic Neuroprotection with Atremorine in ParkinsonÂ´s Disease. Current Medicinal Chemistry, 2019, 25, 5372-5388.	1.2	9
169	Validating Immunotherapy in Alzheimer's Disease: The EB101 Vaccine. Current Pharmaceutical Design, 2016, 22, 849-858.	0.9	9
170	Can Probiotics Cure Inflammatory Bowel Diseases?. Current Pharmaceutical Design, 2016, 22, 904-917.	0.9	9
171	Suicide and Suicide Attempts in the Elderly Patients: An Epidemiological Analysis of Risk Factors and Prevention. Current Pharmaceutical Design, 2020, 26, 2231-2236.	0.9	9
172	Feasibility of Targeting Glioblastoma Stem Cells: From Concept to Clinical Trials. Current Topics in Medicinal Chemistry, 2020, 19, 2974-2984.	1.0	9
173	The Dopaminergic Dysfunction and Altered Working Memory Performance of Aging Mice Lacking Gamma-synuclein Gene. CNS and Neurological Disorders - Drug Targets, 2018, 17, 604-607.	0.8	9
174	Design of a hybrid nanostructure based on fullerene C60 and biologically active substance for modeling physiological properties of compounds. Russian Chemical Bulletin, 2014, 63, 2375-2382.	0.4	8
175	A Critical Appraisal of Different Food Safety and Quality Management Tools to Accomplish Food Safety. , 2018, , 1-12.		8
176	Comparing the Treatment of Congenital Spine Deformity Using Freehand Techniques In Vivo and 3D-Printed Templates In Vitro (Prospectiveâ€“Retrospective Single-Center Analytical Single-Cohort) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		8
177	Glycolytic and Proteolytic Metabolism in Erythrocytes from Elderly and Demented Patients. American Journal of Neuroprotection and Neuroregeneration, 2012, 4, 73-77.	0.1	8
178	Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice. Current Molecular Medicine, 2015, 15, 462-468.	0.6	8
179	Cerebrospinal Fluid, Brain Electrolytes Balance, and the Unsuspected Intrinsic Property of Melanin to Dissociate the Water Molecule. CNS and Neurological Disorders - Drug Targets, 2018, 17, 743-756.	0.8	8
180	The Role of Stem Cells in the Therapy of Stroke. Current Neuropharmacology, 2022, 20, 630-647.	1.4	7

#	Article	IF	Citations
181	Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms. Current Medicinal Chemistry, 2019, 25, 5389-5394.	1.2	7
182	A Systematic in-silico Analysis of Helicobacter pylori Pathogenic Islands for Identification of Novel Drug Target Candidates. Current Genomics, 2017, 18, 450-465.	0.7	7
183	Pharmacological Aspects of Neuro-Immune Interactions. Current Pharmaceutical Design, 2018, 24, 15-21.	0.9	6
184	Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis. International Journal of Molecular Sciences, 2020, 21, 6521.	1.8	6
185	Novel MicroRNA Binding Site SNPs and the Risk of Clear Cell Renal Cell Carcinoma (ccRCC): A Case-Control Study. Current Cancer Drug Targets, 2021, 21, 203-212.	0.8	6
186	The Role of Mitochondria in Piperine Mediated Cardioprotection in Isoproterenol Induced Myocardial Ischemia. Current Pharmaceutical Design, 2021, 27, 2975-2989.	0.9	6
187	E-MHK-0103 (Mineraxinâ„¢): A Novel Nutraceutical with Biological Properties in Menopausal Conditions. Current Drug Metabolism, 2017, 18, 39-49.	0.7	6
188	Chemosensitizing Activity of Histone Deacetylases Inhibitory Cyclic Hydroxamic Acids for Combination Chemotherapy of Lymphatic Leukemia. Current Cancer Drug Targets, 2018, 18, 365-371.	0.8	6
189	The Use of Fibrin-based Tissue Adhesives for Breast in Reconstructive and Plastic Surgery. Current Topics in Medicinal Chemistry, 2020, 19, 2985-2990.	1.0	6
190	Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning. Central Nervous System Agents in Medicinal Chemistry, 2015, 15, 99-108.	0.5	6
191	Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders â€“ Contemporary Approaches. CNS and Neurological Disorders - Drug Targets, 2011, 10, 175-183.	0.8	6
192	A synopsis on the linkage between age-related dementias and vascular disorders. CNS and Neurological Disorders - Drug Targets, 2016, 15, 250-258.	0.8	6
193	A 60-month follow-up of a naturalistic study of integrative treatment for real-life geriatric patients with depression, dementia and multiple chronic illnesses. Open Journal of Psychiatry, 2012, 02, 129-140.	0.2	6
194	Mitochondrial abnormalities mark vulnerable neurons in APP YAC transgenic mice. Neurobiology of Aging, 2000, 21, 267.	1.5	5
195	Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease. , 2014, , 366-386.		5
196	New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 597-610.	0.9	5
197	Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice. Current Genomics, 2017, 18, 408-415.	0.7	5
198	The Posterior Perforated Substance: A Brain Mystery Wrapped in an Enigma. Current Topics in Medicinal Chemistry, 2020, 19, 2991-2998.	1.0	5

#	Article	IF	Citations
199	Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders. CNS and Neurological Disorders - Drug Targets, 2016, 15, 301-309.	0.8	5
200	Classification (Agonist/Antagonist) and Regression â€œStructure-Activityâ€•Models of Drug Interaction with 5-HT6. Central Nervous System Agents in Medicinal Chemistry, 2018, 18, 213-221.	0.5	4
201	Histomorphological and Functional Features of the Eutopic Endometrium in Patients with Ovarian Endometriosis After Surgeryâ€”a Clinical Study. Reproductive Sciences, 2021, 28, 2350-2358.	1.1	4
202	PeMtb: A Database of MHC Antigenic Peptide of Mycobacterium tuberculosis. Current Pharmaceutical Biotechnology, 2017, 18, 648-652.	0.9	4
203	The Prevalence of Epilepsy in the Nakhichevan Autonomous Republic of Azerbaijan. CNS and Neurological Disorders - Drug Targets, 2012, 11, 102-109.	0.8	4
204	Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia. Molecular Neurobiology, 2022, 59, 2472-2496.	1.9	4
205	Computational Analysis and Functional Prediction of Ubiquitin Hypothetical Protein: A Possible Target in Parkinson Disease. Central Nervous System Agents in Medicinal Chemistry, 2015, 16, 4-11.	0.5	3
206	Medicinal Plants in Management of Type 2 Diabetes and Neurodegenerative Disorders. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-2.	0.5	3
207	Editorial (Thematic Issue: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and) Tj ETQq1 1 0.784314 rgBT /Over	0.8	3
208	The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity. Central Nervous System Agents in Medicinal Chemistry, 2019, 19, 215-222.	0.5	3
209	Assessment of Psychosocial Functioning of Mothers of Children with Diabetes Mellitus Compared to Mothers of Healthy Children. BioMed Research International, 2019, 2019, 1-10.	0.9	3
210	Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns. Current Medicinal Chemistry, 2021, 28, 8517-8533.	1.2	3
211	The Beneficial Effects of QIAPI 1Â® against Pentavalent Arsenic-Induced Lung Toxicity: A Hypothetical Model for SARS CoV2-I nduced Lung Toxicity. Current Pharmaceutical Biotechnology, 2022, 23, 307-315.	0.9	3
212	Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Development Research, 2021, 82, 695-706.	1.4	3
213	Approaches of the Transcriptomic Analysis in Astrocytes: Potential Pharmacological Targets. Current Pharmaceutical Design, 2017, 23, 4189-4197.	0.9	3
214	Synthesis and Cytotoxic Activity of Azine Derivatives of 6-Hydroxyxanthanodiene. Current Cancer Drug Targets, 2020, 20, 666-674.	0.8	3
215	Differential Up-Regulation of Ammonia Detoxifying Enzymes in Cerebral Cortex, Cerebellum, Hippocampus, Striatum and Liver in Hyperammonemia. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1089-1095.	0.8	3
216	Unsuspected Intrinsic Property of Melanin to Dissociate Water Can Be Used for the Treatment of CNS Diseases. CNS and Neurological Disorders - Drug Targets, 2016, 15, 135-140.	0.8	3

#	Article	IF	Citations
217	Linkage of Stress with Neuromuscular Disorders. CNS and Neurological Disorders - Drug Targets, 2016, 15, 321-328.	0.8	3
218	Oxidative Damage and Antioxidant Responses in Alzheimer's Disease. , 0, , 371-378.		2
219	The Three-Vessel Occlusion as a Model of Vascular Dementia â€“ Oxidative Stress and Mitochondrial Failure as an Indicator of Brain Hypoperfusion. , 2009, , 2023-2032.		2
220	Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers). Current Pharmaceutical Design, 2016, 22, 765-767.	0.9	2
221	Cardiovascular drugs and triazole based kinase inhibitors as a new strategies for the treatment of Alzheimer disease. Russian Chemical Bulletin, 2016, 65, 1151-1159.	0.4	2
222	Implication of Oxidative Stress-Induced Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegeneration and Cancer. , 2011, , 2325-2347.		2
223	Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations. Current Pharmaceutical Design, 2020, 26, 2221-2230.	0.9	2
224	Can Erythrocyte Catalase Regulate Blood Pressure?. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2016, 14, 49-52.	0.4	2
225	Flavones from the Root of Scutellaria baicalensis Georgi â€“ Drugs of the Future in Neurodegeneration and Neuroprotection?. , 2011, , 2305-2323.		1
226	Role of Î±-Lipoid Acid and Acetyl-L-Carnitine in Dementia. , 2015, , 955-962.		1
227	Editorial: Genomics and Epigenomics of Tumor and Aging Cells. Current Genomics, 2017, 18, 375-377.	0.7	1
228	A Novel Heterocyclic System Based on Natural Epoxyalantolactone. Frontiers in Chemistry, 2019, 7, 655.	1.8	1
229	Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies. Current Neuropharmacology, 2019, 17, 198-200.	1.4	1
230	Colorectal Serrated Lesions: A Current View on Clinical, Morphological, Molecular, and Genetic Diagnostic Criteria. Current Medicinal Chemistry, 2021, 28, 8496-8516.	1.2	1
231	Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia â€“ Potential Probing for Markers. , 2012, , 2289-2304.		1
232	Quality of Life and Social Support in Women with Urinary Incontinence. Current Women's Health Reviews, 2019, 15, 123-129.	0.1	1
233	Antifertility Activity of Lac (Laccifer lacca Kerr.) in Female Wistar Rat Model. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2016, 16, 39-48.	0.5	1
234	A Novel Non-invasive Effective Method for Potential Treatment of Degenerative Disc Disease: A Hypothesis. Central Nervous System Agents in Medicinal Chemistry, 2019, 19, 8-14.	0.5	1

#	Article	IF	Citations
235	Updated Understanding of the Degenerative Disc Diseases - Causes Versus Effects - Treatments, Studies and Hypothesis. Current Genomics, 2020, 21, 464-477.	0.7	1
236	The Long-Term Effect of Medically Enhancing Melanin Intrinsic Bioenergetics Capacity in Prematurity. Current Genomics, 2020, 21, 525-530.	0.7	1
237	Mitochondrial autophagocytosis in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434.	0.9	0
238	Atherosclerotic Lesions and Mitochondrial DNA Deletions as a Primary Hallmark of the Brain Microcirculation â€“ Implication in the Pathogenesis of Alzheimerâ€™s Disease. , 2008, , 2127-2145.		0
239	Oxidative Stress-Induced Mitochondrial Damage as a Hallmark for Drug Development in the Context of the Neurodegeneration, Cardiovascular, and Cerebrovascular Diseases. , 2011, , 2083-2126.		0
240	Potential Preventive Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion. , 2011, , 2033-2048.		0
241	Preface:. Central Nervous System Agents in Medicinal Chemistry, 2015, 15, 3-3.	0.5	0
242	Extensive tracheal resection in lung cancer and tuberculosis: a case report. BMC Pulmonary Medicine, 2020, 20, 197.	0.8	0
243	The Modulation of Beneficial and/or Harmful Effects of Free Oxygen Radicals in the Context of Molecular Mechanisms Regarding Drug â€“ PART I. Current Topics in Medicinal Chemistry, 2020, 19, 2937-2939.	1.0	0
244	Metal Homeostasis and Its Relation to Oxidative Stress in Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2003, , .	0.3	0
245	Mitochondrial Autophagocytosis in Alzheimer Disease. FASEB Journal, 2007, 21, A73.	0.2	0
246	The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. FASEB Journal, 2008, 22, 167.3.	0.2	0
247	Alzheimer Disease: Oxidative Stress and Compensatory Responses. , 2009, , 109-120.		0
248	Meet Our Editorial Board Members:. Current Genomics, 2015, 16, 213-213.	0.7	0
249	Meet Our Editor:. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2015, 15, 99-99.	0.5	0
250	Meet Our Section Editor:. Current Pharmaceutical Biotechnology, 2016, 17, 751-752.	0.9	0